|
Friday, 12 March 2010 15:22 |
 Oculus Innovative Sciences, Inc. (Nasdaq: OCLS - News), a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel. |
|
Read more...
|
|
Friday, 12 March 2010 13:17 |
 InterMune, Inc. (Nasdaq:ITMN - News) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. |
|
Read more...
|
|
Thursday, 11 March 2010 14:49 |
 The Board of Ark Therapeutics Group plc ("Ark" or "the Company") today announces an update relating to the Marketing Authorisation Application ("MAA") for its brain cancer treatment, Cerepro®. Following a presentation to the EMEA's Scientific Advisory Group on Oncology ("SAG-O") as part of the re-examination procedure, the SAG-O did not consider that the current study provides sufficiently reliable evidence of clinical benefit. |
|
Read more...
|
|
Wednesday, 10 March 2010 13:09 |
|
 Luminetx®, a division of Christie Medical Holdings, Inc. and recently acquired by Christie Digital Systems USA, Inc., has signed an exclusive national sales distribution agreement with New Alliance of Independent Medical Distributors, Inc., DBA Alliance Medical. |
|
Read more...
|
|
Wednesday, 10 March 2010 12:04 |
 GeneGo announces the release of the first set of tools and content to come out of its industry-FDA MetaTox? partnership program. The MetaTox partnership is developing a unique comprehensive systems toxicology suite designed for compound safety assessment in chemical and pharmaceutical R&D. |
|
Read more...
|
|
Tuesday, 09 March 2010 13:56 |
 Merck & Co. and its Schering unit is suing Teva Pharmaceutical Industries Ltd. to prevent it from selling a generic version of the cholesterol drug Vytorin in the United States until 2017. |
|
Read more...
|
|
Monday, 08 March 2010 16:35 |
|
 U.S. health regulatory staff are concerned about unclear trial results and possible side effects with InterMune Inc's (ITMN.O) drug for lung scarring, but investors who were braced for a more negative analysis sent the company's shares soaring.
|
|
Read more...
|
|
Monday, 08 March 2010 12:26 |
 XenoPort, Inc. (Nasdaq:XNPT) announced today a restructuring that includes an overall reduction in its workforce of approximately 50%. The restructuring is designed to focus the Company’s resources on advancement of its later-stage product candidates. |
|
Read more...
|
|
Saturday, 06 March 2010 15:08 |
 Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) and Advanced Medical Imaging and Genetics (Amigenics) (www.amigenics.com), an innovative medical clinic specializing in prevention and early detection of disease, announced their intent to collaborate on a variety of projects to advance technology for the early detection of lung and other cancer. |
|
Read more...
|
|
Friday, 05 March 2010 17:59 |
|
 Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Norditropin(R) FlexPro(R) (somatropin [rDNA origin] injection), a pre-filled injection pen to be used by children and adults with growth hormone disorders. It will be available in the second quarter.
|
|
Read more...
|
|
|
Friday, 12 March 2010 14:20 |
 Allergan, Inc. (NYSE: AGN - News) today announced that the United States Food and Drug Administration (FDA) has approved BOTOX® (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity. |
|
Read more...
|
|
Thursday, 11 March 2010 16:53 |
 AutoImmune Inc. (OTC Bulletin Board: AIMM) today announced that its Board of Directors has determined, after consideration of potential strategic alternatives, that it is in the best interests of the Company and its stockholders to liquidate the Company's assets and to dissolve the Company. |
|
Read more...
|
|
Thursday, 11 March 2010 13:46 |
 Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program. |
|
Read more...
|
|
Wednesday, 10 March 2010 12:59 |
|
 Olink Bioscience has signed a distributorship agreement with the Chinese distributor Multisciences Biotech Co., Ltd for distribution of the Duolink® product line in China.
|
|
Read more...
|
|
Tuesday, 09 March 2010 14:59 |
|
 Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics’ unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma’s early drug discovery.
|
|
Read more...
|
|
Tuesday, 09 March 2010 12:53 |
 VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today at the 2010 DNA Vaccines Conference the expansion of its state-of-the-art cGMP plasmid manufacturing facility in The Woodlands, TX. |
|
Read more...
|
|
Monday, 08 March 2010 13:33 |
 La Jolla Pharmaceutical Company (Pink Sheets: LJPC) today announced that La Jolla and Adamis Pharmaceuticals Corporation /quotes/comstock/11k!admp (ADMP 0.29, -0.01, -3.33%) have agreed to terminate their merger agreement relating to the proposed merger of the two companies. |
|
Read more...
|
|
Saturday, 06 March 2010 17:14 |
 In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo (p=0.001). |
|
Read more...
|
|
Saturday, 06 March 2010 13:01 |
|
 Ranbaxy Laboratories (RANB.BO) said on Wednesday it would not be able to launch a generic urinary drug as per schedule in the absence of a final regulatory approval, sending its shares down more than 6 percent.
|
|
Read more...
|
|
Friday, 05 March 2010 16:54 |
 PTC Therapeutics, Inc. and Genzyme Corporation /quotes/comstock/15*!genz/quotes/nls/genz (GENZ 57.23, +0.41, +0.72%) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD). |
|
Read more...
|
|
